Smith Thornton Advisors’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$713K Hold
4,908
– – 0.31% 66
2026
Q2
$609K Buy
4,908
+473
+11% +$55.4K 0.27% 74
2026
Q1
$534K Hold
4,435
– – 0.27% 79
2025
Q4
$467K Buy
4,435
+56
+1% +$5.26K 0.24% 86
2025
Q3
$368K Buy
4,379
+42
+1% +$3.46K 0.19% 99
2025
Q2
$343K Sell
4,337
-30
-0.7% -$2.38K 0.2% 105
2025
Q1
$392K Sell
4,367
-731
-14% -$68.3K 0.24% 87
2024
Q4
$507K Buy
5,098
+566
+12% +$58.4K 0.32% 78
2024
Q3
$515K Buy
4,532
+130
+3% +$15.4K 0.34% 78
2024
Q2
$545K Buy
+4,402
New +$567K 0.4% 69

Other funds holding MRK

Smith Thornton Advisors's MRK Position: Q3 2026 in Review

Smith Thornton Advisors held its Merck (MRK) position steady in Q3 2026 at 4,908 shares worth $713K. The position accounts for 0.31% of the portfolio, ranked #66.

Smith Thornton Advisors first reported a position in MRK in Q2 2024 and has held it in 10 quarters since. 3,953 funds tracked by Wall St. Rank hold MRK as of Q3 2026.

  • Smith Thornton Advisors held 4,908 shares of Merck worth $713K as of Q3 2026.
  • Smith Thornton Advisors left its Merck share count unchanged in Q3 2026.
  • Merck made up 0.31% of Smith Thornton Advisors's portfolio in Q3 2026, its #66 holding.
  • Smith Thornton Advisors first reported a position in Merck in Q2 2024 and has held it in 10 quarters since.
  • 3,953 funds tracked by Wall St. Rank held Merck as of Q3 2026.

Based on Smith Thornton Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.